tirzepatide weight loss nejm SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean at the highest dose. 57% of participants The results are finally in

Log it: Note the injection date and site in a journal or phone app to ensure proper rotation

Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data

This is achieved through a combination of lifestyle changes, such as healthy eating and exercise, and medical interventions, such as medications

The Labeled Population Is the Starting Point Wegovy injection is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition